• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Seagen, Merck put $1.6B ADC collab on the back burner citing 'emerging treatment...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Aug 03, 2023 at 06:42: PM
via Seagen is putting a phase 2 Merck & Co.-partnered antibody-drug conjugate on the shelf for now, nearly three years after signing on to a $1.6 billion partnership for the asset.

article source
 

<



Similar threads

cafead
BMS chases Merck/Seagen with first-line bladder cancer filing
Replies
0
Views
65
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ESMO: Seagen, Astellas and Merck knock it out of the park with Padcev-Keytruda combo in...
Replies
0
Views
125
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Merck, Seagen and Astellas Get Late-Stage Win in Bladder Cancer with Combo
Replies
0
Views
56
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Seagen mum on Merck buyout rumors as it bats for blockbuster with Adcetris
Replies
0
Views
287
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Seagen secures a speedy FDA review on Tukysa as Merck buyout talks reportedly stall
Replies
0
Views
397
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote